AC Immune Shares Insights from Key Opinion Leader Meeting on Tau as a Therapeutic and Diagnostic Target in Alzheimer's and other Neurodegenerative Diseases
December 01, 2017 14:20 ET
|
AC Immune SA
Lausanne, Switzerland, December 1, 2017 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, shared...
AC Immune to Host Key Opinion Leader Meeting on Tau as a Therapeutic and Diagnostic Target in Alzheimer's and other Neurodegenerative Diseases
November 21, 2017 08:31 ET
|
AC Immune SA
Lausanne, Switzerland, November 21, 2017 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today...
AC Immune SA Reports Third Quarter 2017 Financial Results and Corporate Update
November 13, 2017 06:47 ET
|
AC Immune SA
Expansion of pipeline with two new antibodies against proteins alpha-synuclein and TDP-43 Recruitment of first cohort completed for anti-beta vaccine targeting Alzheimer's symptoms in adults...
AC Immune SA to Receive Milestone Payment for Anti-Tau Antibody Moving into Phase 2 Trial for Alzheimer's Disease
November 02, 2017 06:22 ET
|
AC Immune SA
AC Immune to receive third milestone payment of CHF 14 million under collaboration agreement with Genentech Phase 2 to evaluate effects of anti-Tau antibody in...
AC Immune to Present at Two Investor Conferences and Provide Scientific Updates at CTAD Conference
October 24, 2017 05:40 ET
|
AC Immune SA
AC Immune to Present at Two Investor Conferences and Provide Scientific Updates at CTAD Conference Lausanne, Switzerland, - October 24, 2017 - AC Immune SA (NASDAQ: ACIU), a Swiss-based,...
AC Immune Awarded Continuation of 2015 Grant from The Michael J. Fox Foundation for Parkinson's Research
October 03, 2017 04:53 ET
|
AC Immune SA
Continued development of PET tracer for earlier and more accurate diagnosis of Parkinson's disease Focuses on alpha-synuclein, a key protein in Parkinson's disease pathology Lausanne,...
AC IMMUNE COMPLETES RECRUITMENT FOR LOW-DOSE COHORT IN WORLD'S FIRST CLINICAL TRIAL FOR ANTI-ABETA VACCINE TARGETING ALZHEIMER'S DISEASE-LIKE CHARACTERISTICS IN INDIVIDUALS WITH DOWN SYNDROME
September 12, 2017 06:04 ET
|
AC Immune SA
AC Immune completes Recruitment for Low-Dose Cohort of Participants in World's First Clinical Trial for anti-Abeta Vaccine Targeting Alzheimer's Disease-like Characteristics in Individuals with Down...
AC IMMUNE DISCOVERS NEXT-GENERATION ANTIBODIES FOCUSED ON NEURODEGENERATIVE DISEASES
August 22, 2017 04:24 ET
|
AC Immune SA
Pipeline expansion with new antibodies against alpha-synuclein and TDP-43 Proprietary scientific approach rapidly delivers high-quality assets Execution of clear strategy around three pillars ...
AC IMMUNE REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS
August 09, 2017 06:44 ET
|
AC Immune SA
Strong cash position of CHF 124.2 million provides resources to advance pipeline of seven therapeutic and three diagnostic candidates Increased R&D investment across three pillars of...
AC IMMUNE PROVIDES SEVEN UPDATES ON ITS PIPELINE AND TECHNOLOGY AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE
July 10, 2017 07:55 ET
|
AC Immune SA
Lausanne, Switzerland, July 10, 2017 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company focused on neurodegenerative diseases, today announced that seven updates...